Extending human healthspan by 30+ years

Leading the mission to democratize longevity technologies through cutting-edge biotechnology and accessible healthcare.

Visionary Entrepreneur & Biotechnology Pioneer

Boris Djordjevic is a builder at the frontier of longevity—an entrepreneur who pairs scientific rigor with practical delivery. As the founder and CEO of 199, he leads an integrated effort to add decades of healthy life, shaping a system where research compounds, clinics translate, and diagnostics scale.

At 199 Biotechnologies, his team advances research in partial cellular reprogramming and senolytics, including Procyanidin C1 (PCC1). The emphasis is translational: define clear endpoints, design safe delivery, and move credible rejuvenation biology along a path that can reach people—not just papers.

That scientific engine is coupled to care. 199 Longevity Clinic delivers personalized, evidence‑based programs grounded in rigorous diagnostics and longitudinal follow‑up. In parallel, 199 Labs pushes discovery forward across gene therapies, peptides, and pharmaceutical development—tight feedback between assay, candidate, and clinic.

199 Diagnostics (AgeQuant) makes measurement accessible, from testing kits for key biomarkers to a new diagnostics platform built on digital microfluidics. In a joint venture with TripleHelix, Boris extends this pipeline into gene‑therapy clinical applications. The through‑line is simple and demanding: turn promising science into outcomes, with precision, integrity, and speed.

Consulting

Two high‑touch offerings: bespoke clinical consulting for individuals and strategic advisory for longevity biotech companies.

Longevity & Rare Diseases

Through 199 Longevity Clinic and our partners, we provide bespoke services for complex medical cases and rare diseases—focusing on early diagnosis, prevention, and adjuvant care alongside patients’ primary physicians.

• Coordinated, expert second opinions and case navigation
• Advanced diagnostics and longitudinal biomarker tracking
• Personalized protocols integrated with standard-of-care

Longevity Biotech Advisory

Advisory for longevity and pharmaceutical companies on sustainability, fundraising, scale‑up, and commercialization—leveraging a wide network across longevity, pharma, and global distribution.